Search trials – HealthDB

Активни:

Намерени 4,781 изпитвания Стр. 156 от 240

Not yet recruiting Early Phase 1

CTZ Paste for Emergency Dental Treatment in Public Health Settings: A Randomized Trial

Pulp Disease, Dental Pulp Necrosis Pulp Therapy in Primary Molars Primary Teeth +6

The treatment of pulpal diseases in primary teeth represents a significant challenge in public health, particularly in emergency dental care settings, where factors such as limited clinical time, low child cooperation, and structural constraints directly impact treatment effectiveness. In these contexts, conventional pulpectomy using zinc oxide-eugenol (ZOE), although effective, may present operational limitations that restrict its large-scale applicability in public health systems. In this scenario, non-instrumental endodontic treatment (NIET), based on the concept of Lesion Sterilization and Tissue Repair (LSTR), has emerged as a simplified alternative. Among the available options, CTZ paste shows potential for single-visit application, reducing clinical time and technical complexity. This study aims to evaluate the clinical and radiographic non-inferiority of CTZ paste compared to conventional pulpectomy with ZOE in primary molars with pulp necrosis, with or without abscess or fistula, treated in emergency dental care settings. This is a randomized, pragmatic, controlled, non-inferiority clinical trial conducted at a single center, with clinical and radiographic follow-up at 3, 6, and 12 months. Participants will be allocated into two groups: (1) NIET with CTZ paste and (2) conventional pulpectomy with ZOE. Primary outcomes include pain resolution and absence of clinical signs of infection. Secondary outcomes include radiographic success, clinical time, child behavior (Frankl Scale), need for retreatment, and oral health-related quality of life. The findings are expected to provide robust evidence regarding the effectiveness of CTZ paste under real-world clinical conditions, contributing to the development of more accessible and effective protocols within public health systems, with the potential to expand access to conservative treatment and reduce early tooth extractions in pediatric dentistry.

Начало: 08.06.2026 Край: 28.02.2028 Възраст: 2–11 г.

University of Sao Paulo NCT07542639

Not yet recruiting

Effectiveness of a Combined Aloe Vera-Peppermint Gel on Prevention Pressure Injuries Among Intensive Care Unit Patients

Pressure Injury

The goal of this clinical trails is to learn if a combined Aloe Vera-Peppermint gel work to prevent pressure injuries (bedsores) in ICU patients. Does applying this natural gel reduce the incidence of pressure injuries compared to standard care? participants will be randomly assigned to either receive the gel application (Aloe Vera-Peppermint gel) or the standard hospital nursing care.

Начало: 05.06.2026 Край: 20.04.2027 Възраст: от 18 г.

Iraq Ali Abd-Alredha Hussein NCT07537101

Not yet recruiting

Pediatric Renal Emergencies: Presentations and Outcomes at Sohag University Hospitals

Kidney Diseases

Renal diseases in children present with a wide spectrum of clinical manifestations, ranging from mild urinary abnormalities to severe acute kidney injury requiring urgent management. Early recognition in the emergency setting is essential to improve outcomes, yet data on pediatric renal emergencies in Upper Egypt remain limited. This prospective cohort study aims to characterize the clinical presentations of renal diseases among children presenting to the emergency room at Sohag University Hospitals, determine the prevalence of specific renal conditions, and evaluate immediate management outcomes and short-term follow-up after discharge.

Начало: 05.06.2026 Край: 05.10.2027 Възраст: 1–18 г.

Sohag University NCT07543549

Not yet recruiting Phase 3

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Lung Non-Small Cell Carcinoma

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach.

Начало: 05.06.2026 Край: 30.09.2029 Възраст: от 18 г.

National Cancer Institute (NCI) NCT07388524

Not yet recruiting Phase 2

Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases

Breast Cancer Brain Metastases HR+/HER2- Breast Cancer

This is a prospective, open-label, exploratory clinical trial designed to evaluate the efficacy and safety of brain radiotherapy combined with dalpiciclib and endocrine therapy in HR-positive/HER2-negative advanced breast cancer patients with brain metastases. A total of 46 patients are planned to be enrolled. Participants will receive dalpiciclib plus endocrine therapy and brain radiotherapy, including fractionated stereotactic radiotherapy (FSRT) or whole-brain radiotherapy (WBRT), according to the clinical characteristics of brain metastatic lesions. Radiotherapy may start within 30 days before or after initiation of drug treatment. Dalpiciclib and endocrine therapy may be given concurrently during radiotherapy and will be continued after radiotherapy until disease progression, intolerable toxicity, withdrawal of informed consent, or investigator decision. Participants will visit the clinic once every 3 months for checkups and tests. Tumor response will be assessed according to RECIST version 1.1, and safety will be evaluated throughout the study.

Начало: 01.06.2026 Край: 01.08.2029 Възраст: 18–75 г.

China Nanfang Hospital, Southern Medical University NCT07539753

Not yet recruiting Early Phase 1

Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques

Carotid Artery Diseases Peripheral Arterial Disease

Active inflammation plays a key role in causing Coronary Artery Disease (CAD) and Peripheral Arterial Disease (PAD). Since inflammation is so important in how these diseases start, are diagnosed, and treated, being able to see it clearly in each patient could lead to more personalized and effective care - and may help prevent heart attacks. Right now, there's no imaging technology available to clearly see inflammation inside the coronary arteries. The investigators hope to learn how an imaging drug; called LUMISIGHT (Pegulicianine) can help detect inflammation in blood vessels compared with saline. If the investigators find out that LUMISIGHT is active in humans, the investigators might be able to use it for detecting plaque risk in the future.

Начало: 01.06.2026 Край: 01.12.2029 Възраст: от 18 г.

United States Massachusetts General Hospital NCT06957821

Not yet recruiting Phase 2

Computerized Cognitive Behavioral Therapy-Depression (cCBT-D) for Caregivers of Veterans

Depression

Preliminary evaluation a caregiver cCBT-D protocol, including changes in psychosocial functioning and mental health symptoms as well as perceptions of feasibility, acceptability, and safety.

Начало: 01.06.2026 Край: 31.10.2026 Възраст: 18–65 г.

VA Eastern Colorado Health Care System NCT07547709

Not yet recruiting

Navigation for Elderly People With Multiple Morbidity After Hospital Discharge.

Multimorbidity

This research aims to create and test a tracking (navigation) model to assist in providing care guidance to elderly people (60 years or older) who have two or more chronic diseases at the same time (multimorbidity) immediately after being discharged from the hospital.

Начало: 01.06.2026 Край: 30.03.2028 Възраст: от 60 г.

Brazil Hospital de Clinicas de Porto Alegre NCT07546006

Not yet recruiting Phase 1

A Study of LY3971297 in Participants With Heart Failure

Heart Failure Heart Failure, Diastolic Heart Failure, Systolic

The main purpose of this study is to assess how well LY3971297 is tolerated and what side effects may occur in participants with heart failure with preserved ejection fraction (HFpEF) and participants with heart failure with reduced ejection fraction (HFrEF). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 2 months and will include 1 inpatient visit lasting approximately 4 days and 5 outpatient visits.

Начало: 01.06.2026 Край: 01.08.2027 Възраст: 18–65 г.

Japan, United States Eli Lilly and Company NCT07547540

Not yet recruiting

CARRII Native Intervention Optimization Trial

Fetal Alcohol Spectrum Disorders Pregnancy Alcohol-Related Disorders Drinking, Alcohol +3

The purpose of this study is to identify the best combination of new intervention components to use with CARRII, the first automated online intervention for alcohol-exposed pregnancies (AEP). This intervention is specifically designed for Native women and others who can become pregnant. Our goal is to maximize the effectiveness of the online intervention while keeping costs manageable for Native communities.

Начало: 01.06.2026 Край: 30.04.2028 Възраст: 18–44 г.

United States University of Virginia NCT07547696

Not yet recruiting

Machine Learning Enabled Management of Behavioural and Psychological Symptoms of Dementia Intervention for Dementia Caregivers

Dementia Caregiver

Develop and test a machine learning enabled management of behavioural and psychological symptoms of dementia intervention for dementia caregivers.

Начало: 01.06.2026 Край: 30.11.2027 Възраст: от 18 г.

Hong Kong Education University of Hong Kong NCT07444866

Not yet recruiting Phase 1/2

SKB565 for Injection in Advanced Solid Tumors

Advanced Solid Tumors

This is a phase I/II clinical study to evaluate the safety and efficacy of SKB565 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.

Начало: 01.06.2026 Край: 01.05.2029 Възраст: 18–75 г.

China Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. NCT07545265

Not yet recruiting

Prospective Post Market Clinical Registry for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH Spring System Registry

BPH (Benign Prostatic Hyperplasia)

The purpose of this registry is to collect information on how the Zenflow Spring System works in everyday medical practice. The registry will track how the Spring System performs during the implant procedure, and at follow-up visits at 1, 3, 6, and 12 months. We will look at how symptoms improve, how quickly patients return to normal activities, how satisfied they are with treatment, and whether there are any problems or side effects related to the device.

Начало: 01.06.2026 Край: 01.09.2028 Възраст: от 18 г.

United States Zenflow, Inc. NCT07538622

Not yet recruiting Phase 1

A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

This is a 2-part, first-in-human, open-label study to determine the safety, tolerability and preliminary efficacy of KIVU-305, a CEACAM5-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.

Начало: 01.06.2026 Край: 01.12.2029 Възраст: от 18 г. Treatment

Australia Kivu Bioscience Inc. NCT07545356

Not yet recruiting

Role of the Environment in Pediatric Obesity

Obesity (Disorder)

Childhood obesity is a particular concern in developed countries such as the United States, the United Kingdom, Canada, and certain European countries. According to the World Health Organization (WHO), approximately 6% of children under the age of 5 worldwide were obese in 2016, a figure that continues to rise. The pathophysiology of pediatric obesity can be explained by several interconnected biological and behavioral mechanisms. In particular, it involves dysfunctions in the hormones that regulate appetite and satiety, as well as dysfunctions in lipid metabolism. Per- and polyfluoroalkyl substances (PFAS) are a large family of synthetic chemical compounds. The main PFAS are perfluorooctanoic acid (PFOA), perfluorooctanesulfonic acid (PFOS), perfluorononanoic acid (PFNA), and perfluorohexanesulfonic acid (PFHxS). PFAS are present in many everyday consumer products. Bisphenol A (BPA) is a chemical compound used primarily in the manufacture of plastics and resins. It is commonly found in polycarbonate plastics, used to make food containers and water bottles, as well as in epoxy resins, which are used to coat the inside of food cans and water pipes. Non-persistent pesticides, such as organophosphates and polychlorinated biphenyls, are chemicals used primarily in agriculture to control insects and other pests. There are arguments suggesting that PFAS, bisphenol A, and non-persistent pesticides may play a role in the onset of pediatric obesity, particularly by acting.

Начало: 01.06.2026 Край: 01.06.2029 Възраст: 6–15 г.

France University Hospital, Tours NCT07545174

Not yet recruiting

Clinical Decision Support for Safety of Opioid Transitions

Medication Abuse Harm Reduction

The objective of this study is to evaluate the impact of clinical decision support (CDS) alert to notify providers when the opioid prescription being written will result in the patient transitioning into a new phase of opioid therapy. The 2022 CDC clinical practice guideline for prescribing opioids for pain recommends providers reassess patient pain as well as the risks and benefits of opioid therapy before patients transition from acute to subacute treatment (1 month of opioid analgesics) and when patients transition from subacute to chronic opioid treatment (3 months). This study will evaluate a clinical decision support tool identifying patients who will be transitioning between phases as a result of an opioid prescription and suggest a review of patient pain and goals. Primary care providers will be randomized at the clinic location to a control arm or intervention arm. The control arm will not be notified that the prescription transitions the patient to a new phase but will have access to the same patient pain scales and information. The intervention arm will receive a notification of the transition and suggest review of patient needs and encourage documentation. Opioid transition orders and outcomes of patients will be examined based on medical records data collected during routine care.

Начало: 01.06.2026 Край: 01.06.2027 Възраст: 12–89 г.

University of Colorado, Denver NCT06527040

Not yet recruiting Phase 3

Phenobarbital for Agitated Delirium

Agitated Delirium Delirium Confusional State Delirium in the Intensive Care Unit Hyperactive Delirium

The goal of this clinical trial is to test whether the medication phenobarbital is as effective for treating agitated delirium among adult patients admitted to the intensive care unit. Agitated delirium is a condition involving confusion and impulsiveness which is dangerous to both patients and healthcare providers. The main questions this trial aims to answer include: * Can phenobarbital decrease the amount of time patients with agitated delirium spend in the intensive care unit and the hospital? * Does phenobarbital decrease the amount of additional calming medications patients with agitated delirium need? Researchers in this study will compare phenobarbital to other medications commonly used to treat agitated delirium. Participants will be monitored closely to make sure they remain safe and to measure how well their agitation and confusion are managed while they are in the ICU.

Начало: 01.06.2026 Край: 01.07.2027 Възраст: от 21 г.

United States Duke University NCT07548489

Not yet recruiting

The Effects of Hyaluronic Acid on Skin Health

Skin Health

As people age, skin health gradually changes. The structure and function of the skin are modified, its ability to regenerate decreases, and certain biological changes may accumulate over time. These processes can make the skin more fragile and more sensitive to certain diseases, including skin cancer. In dermatological and aesthetic practice, injectable formulations based on hyaluronic acid are widely used to improve skin quality. Although these products are generally well tolerated, their deeper biological effects are most often assessed through subjective clinical observations. Quantitative scientific data are therefore needed to better understand how these products affect the skin. The aim of this study is to determine whether a hyaluronic acid-based formulation induces measurable changes in biological markers associated with skin health and fibroblast activity, which are important for skin regeneration. The study also examines whether these biological changes are accompanied by internal changes in skin structure. For each participant, three skin areas located on the lower abdomen will be studied. One area will receive an injection of the medical device, a second area will undergo needle insertion without injection, and a third area will receive no intervention. The assignment of the interventions to the skin areas will be done by chance, similar to a coin toss. The participant will know which interventions are performed and on which areas, while the evaluators will not. The study includes three visits over a period of approximately six weeks. Non-invasive examinations as well as three small skin biopsies will be performed. There is no direct benefit expected for participants. The risks are mainly local and temporary. The overall results of the study will be shared after its completion in the form of a summary written in language understandable to the general public.

Начало: 01.06.2026 Край: 01.12.2026 Възраст: 18–50 г.

Switzerland Hans Laubach NCT07542132

Not yet recruiting Phase 2

Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)

Waldenstrom Macroglobulinemia

The purpose of this clinical trial it to test the safety and tolerability of the study drugs mosunetuzumab in combination with pirtobrutinib in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.

Начало: 01.06.2026 Край: 01.06.2035 Възраст: от 18 г.

United States University of Utah NCT07548450

Not yet recruiting

PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels

Amyloidogenic Transthyretin (ATTR) Amyloidosis Cardiac Amyloidosis

The goal of this study is to learn whether PET-CT imaging using evuzamitide can help diagnose transthyretin cardiac amyloidosis (ATTR-CA) in patients whose standard nuclear imaging results are unclear but who have elevated TAD1 levels in their blood. The main question it aims to answer is: Can evuzamitide PET-CT imaging detect signs of cardiac amyloidosis in patients with non-diagnostic nuclear scintigraphy but elevated TAD1 levels? Participants who meet eligibility criteria will receive a single PET-CT scan with evuzamitide and will be followed for approximately 28 days to monitor safety and collect additional clinical information.

Начало: 01.06.2026 Край: 01.04.2028

United States Lorena Saelices NCT07538518

1 … 154 155 156 157 158 … 240